Company news
BioCryst Pharmaceuticals, Inc. news in 2021
BioCryst Pharmaceuticals, Inc.'s news releases, calls and decks from 2021, newest first.
BioCryst Begins Patient Enrollment in REDEEM-2 Pivotal Trial Evaluating BCX9930 as Oral Monotherapy for Patients with PNH
November 28, 2021
BioCryst Adds $350 Million in New Financing with Royalty Pharma and OMERS Capital Markets
November 21, 2021
BioCryst Presents New Data Showing Sustained Reduction of HAE Attack Rates and Improved Patient Satisfaction After Patients Switch to ORLADEYO® (berotralstat)
November 4, 2021
BioCryst Reports Third Quarter 2021 Financial Results and Upcoming Key Milestones
November 2, 2021
BioCryst Appoints Jinky Ang Rosselli Chief Data and Insights Officer
October 31, 2021
BioCryst Appoints Dr. Amy McKee to Board of Directors
September 19, 2021
BioCryst Announces Approval of ORLADEYO® (berotralstat) in United Arab Emirates
September 8, 2021
BioCryst Appoints Dr. Steven Galson to Board of Directors
August 25, 2021
BioCryst Announces Acceptance of Regulatory Applications for ORLADEYO® (berotralstat) by Health Canada and Swissmedic
August 24, 2021
BioCryst Commences Public Offering of Common Stock and Pre-Funded Warrants
August 8, 2021
BioCryst Reports Second Quarter 2021 Financial Results and Upcoming Key Milestones
August 4, 2021
BioCryst Appoints Vincent Milano to Board of Directors
July 27, 2021
BioCryst to Report Second Quarter 2021 Financial Results on August 5
July 21, 2021
BioCryst Announces Designs for REDEEM-1 and REDEEM-2 Pivotal Trials with BCX9930 as Oral Monotherapy for Patients with PNH
July 14, 2021
BioCryst Reports 96-week Data from APeX-2 Showing ORLADEYO®(berotralstat) Reduced HAE Attack Rate by 80 Percent from Baseline
July 9, 2021
BioCryst Announces Acceptance and Accelerated Review of the ORLADEYO™ (berotralstat) Marketing Application by the Israeli Ministry of Health
June 15, 2021
BioCryst Launches ORLADEYO™ (berotralstat) in Germany
June 2, 2021
BioCryst Receives UK Approval of ORLADEYO™ (berotralstat), First Oral, Once-daily Therapy to Prevent Attacks in Hereditary Angioedema Patients
May 11, 2021
BioCryst Reports First Quarter 2021 Financial Results and Upcoming Key Milestones
May 5, 2021
BioCryst Receives European Commission Approval of ORLADEYO™ (berotralstat), First Oral, Once-daily Therapy to Prevent Attacks in Hereditary Angioedema Patients
April 29, 2021
BioCryst to Report First Quarter 2021 Financial Results on May 6
April 21, 2021
BioCryst Announces Approval of Japanese NHI Price Listing of ORLADEYO™ (berotralstat) for Prophylactic Treatment of Hereditary Angioedema
April 13, 2021
BioCryst’s Oral Factor D Inhibitor, BCX9930, Advancing to Pivotal Trials in PNH Following Successful Proof of Concept Trial
March 21, 2021
BioCryst Appoints Helen Thackray, M.D., as Chief Research and Development Officer
March 18, 2021
BioCryst to Host Virtual R&D Day on March 22, 2021
March 14, 2021
BioCryst Submits Marketing Authorization Application for UK Approval of ORLADEYO™ (berotralstat), an Oral, Once-daily Therapy to Prevent Attacks in Patients with Hereditary Angioedema
March 1, 2021
BioCryst Receives Positive CHMP Opinion for ORLADEYO™ (berotralstat), an Oral, Once-daily Therapy to Prevent Attacks in Patients with Hereditary Angioedema
February 24, 2021
BioCryst Announces FDA Approval of Supplemental New Drug Application for RAPIVAB® Expanding Patient Population to Include Children Six Months and Older
February 2, 2021
BioCryst Announces Approval of ORLADEYO™ (berotralstat) in Japan for the Prophylactic Treatment of Hereditary Angioedema
January 21, 2021
Calls in 2021
- BioCryst Pharmaceuticals (NASDAQ:BCRX) Q3 2021 Earnings Call
Nov 3, 2021
Transcript - BioCryst Pharmaceuticals (NASDAQ:BCRX) Q2 2021 Earnings Call
Aug 5, 2021
Transcript - BioCryst Pharmaceuticals (NASDAQ:BCRX) Q1 2021 Earnings Call
May 6, 2021
Transcript - BioCryst Pharmaceuticals (NASDAQ:BCRX) Q4 2020 Earnings Call
Feb 25, 2021
Transcript
Decks in 2021
- Q1 2021 Earnings Presentation
Earnings · 6 slides · May 6, 2021